Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Views

<< 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2012 >>

22 July 2011: Ten tips for enterprising doctoral students

By Stephen Caddick  Vice-Provost (Enterprise) at UCL
It is sometimes assumed that students carrying out research have their career mapped out for them as academics or in a corporate or public research institute.
More...

<< 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2012 >>